Axonics ModulationTechnologies Inc

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Axonics reports record Q4 revenue, eyes global expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q4 2022, with record revenue, solid margins, and profitability, while reiterating revenue guidance for 2023.
The company's focus on innovation, market leadership in sacral neuromodulation, and global expansion plans position it well for future growth despite challenges in international markets and legal uncertainties.
Opportunities in the U.S. and Asian markets, coupled with strategic initiatives like direct-to-consumer campaigns and product enhancements, offer avenues for sustained revenue growth and market dominance.

Axonics reports robust Q1 earnings, eyes market expansion opportunities

Axonics Modulation Technologies Inc delivered strong financial performance in Q1 2023, driven by revenue growth, operational efficiency, and strategic guidance updates for FY 2023.
The company's strengths lie in its robust commercial team, successful marketing campaigns, focus on innovation, and leadership's commitment to disciplined growth strategies.
While facing challenges such as legal uncertainties, coverage limitations, and margin management, Axonics has opportunities for market expansion, acquisitions, and technology advancements.
Overall, Axonics' performance, strengths, challenges, and opportunities position the company for continued growth and market leadership in the neuromodulation industry.

Axonics Modulation Technologies Reports Record Q2 Revenue Growth

Axonics Modulation Technologies delivered a strong performance in Q2, driven by revenue growth and operational efficiency.
The company's strengths lie in international expansion, robust commercial efforts, and continuous product innovation.
Challenges include legal uncertainties, market dynamics, and strategic positioning in a competitive landscape.
Opportunities for growth include market expansion, rising adoption trends, and enhancing customer experience.

Axonics reports robust Q3 earnings, eyes growth through innovation

Axonics delivered strong financial performance, driven by SNM and Bulkamid revenue growth and improved margins.
The company's focus on innovation, customer feedback, and market leadership positions it well for future growth.
Challenges include maintaining growth momentum, high rep productivity, and balancing marketing strategies.
Opportunities lie in expanding product offerings, market share, and leveraging direct-to-consumer campaigns for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific

NEW YORK , Jan. 8, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Axonics, Inc. (NASDAQ: AXNX) and its board of directors concerning the proposed acquisition of the company by Boston Scientific Corporation (NYSE: BSX). Stockholders will receive $71.00 for each share of Axonics stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc.

Axonics (NASDAQ: AXNX ) stock is rising higher on Monday following news that Boston Scientific (NYSE: BSX ) is acquiring the company for $3.7 billion. That has Boston Scientific agreeing to purchase Axonics for $71 in cash per share.

Why Is Axonics (AXNX) Stock Up 20% Today?

The shares of Axonix Inc (NASDAQ:AXNX) are soaring today, after news that Boston Scientific (BSX) is acquiring the medical equipment name for approximately $3.7 billion, or $71 per share.

Axonix Stock Hits 52-Week High on Buyout Buzz

MILWAUKEE , Jan. 8, 2024 /PRNewswire/ -- Ademi LLP is investigating Axonics (Nasdaq: AXNX) for possible breaches of fiduciary duty and other violations of law in its transaction with Boston Scientific . Click here to learn how to join the https://www.ademilaw.com/case/axonics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Axonics, Inc. has obtained a Fair Price in its transaction with Boston Scientific

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Axonics, Inc. (NASDAQ: AXNX) to Boston Scientific Corporation for $71.00 in cash per share is fair to Axonics shareholders. Halper Sadeh encourages Axonics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Axonic.

AXNX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Axonics, Inc. Is Fair to Shareholders

The move will expand Boston's product portfolio in its urology business.

Axonics Stock Soars. It's Being Acquired By Boston Scientific In $3.7 Billion Deal.

Axonics had agreed to be bought for $71 a share. Boston Scientific said the deal gave Axonics an equity value of $3.7 billion and an enterprise value of $3.4 billion.

Boston Scientific To Acquire Axonics For About $3.7 Bln

Boston Scientific said on Monday it had agreed to buy medtech company Axonics Inc for $3.7 billion.

Boston Scientific to buy Axonics for $3.7 billion

Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction MARLBOROUGH, Mass. , Jan. 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily focused on the development and commercialization of differentiated devices to treat urinary and bowel dysfunction.

Boston Scientific Announces Agreement to Acquire Axonics, Inc.

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion. Axonics brings a complementary product portfolio to the Boston Scientific Urology business. Axonics has pioneered and introduced significant enhancements to sacral neuromodulation therapy for bladder and bowel dysfunction and.

Axonics Announces Definitive Agreement to be Acquired by Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023. “The continued strong performance of Axonics reflects the physician community's preference and enthusiasm for our best-in-class incontinence products,” said Raymond W. Cohen, chief exec.

Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024. Interested parties may access a live webcast and replay of the presentation by visiting the Axonics investor relations website. About Axonics Axonics is a global medical techn.

Axonics to Present at the J.P. Morgan Healthcare Conference

HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical technology company developing a total artificial heart (TAH), today announced that Raymond W. Cohen has been appointed chairman of its board of directors. Mr. Cohen is an accredited public company director with over 40 years of experience in the life sciences industry. He currently serves as chief executive officer and member of the board of directors of Axonics, Inc. (Nasdaq: AXNX), an Irvine, Calif. based globa.

BiVACOR Appoints Veteran Medical Device Executive Raymond W. Cohen as Chairman of the Board of Directors

Cava Group, Inc.

Goldman Sachs Small Cap Core Equity ETF

iRhythm Technologies

Meritage Homes

Novo Nordisk

Sweetgreen

Shake Shack

Tenable Holdings Inc

Wingstop

Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which has been the case for funds that track the S&P 500.

Goldman Sachs money manager digs into three themes for long-term growth

Bel Fuse

Thermon Group Hlds

Invest in stocks of Axonics (AXNX), Bel Fuse (BELFB) and Thermon (THR) to tap their high-efficiency levels.

3 Stocks Backed by High Efficiency to Increase Portfolio Returns

The average of price targets set by Wall Street analysts indicates a potential upside of 25.1% in Axonics (AXNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe Axonics (AXNX) Could Rally 25.1%: Here's is How to Trade

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in November: Event: Wolfe Research Healthcare Conference Date: Tuesday, November 14 Presentation time: 12:30 p.m. Eastern Time Event: Piper Sandler Healthcare Conference Date: Wednesday, November 29 Presentation time: 10:30 a.m.

Axonics to Participate in November Investor Conferences

Axonics, Inc. (NASDAQ:AXNX ) Q3 2023 Earnings Conference Call October 30, 2023 4:30 PM ET Company Participants Neil Bhalodkar - Vice President of Investor Relations Raymond Cohen - Chief Executive Officer Kari Keese - Chief Financial Officer Conference Call Participants Chris Pasquale - Nephron Research Larry Biegelsen - Wells Fargo Travis Steed - Bank of America Securities Richard Newitter - Truist Securities Adam Maeder - Piper Sandler Mike Polark - Wolfe Research Mike Matson - Needham & Company David Rescott - Baird Kristen Stewart - CL King Shagun Singh - RBC Capital Markets Anthony Petrone - Mizuho Securities Kallum Titchmarsh - Morgan Stanley Michael Sarcone - Jefferies Mike Kratky - Leerink Partners Operator Ladies and gentlemen, thank you for standing by. Welcome to the Axonics Third Quarter 2023 Results Conference Call.

Axonics, Inc. (AXNX) Q3 2023 Earnings Call Transcript

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2023. “Our commercial team continues to execute at a high level, generating over 30% revenue growth in the third quarter,” said Raymond W. Cohen, chief executive officer. “Our growth was driven by higher utilization and.

Axonics Reports Third Quarter 2023 Financial Results

Arch Capital

ON Semiconductor

Welltower

XPO Logistics

We have narrowed our search to five stocks that are set to declare third-quarter earnings on Monday. These are: XPO, ON, WELL, ACGL, AXNX.

5 Top Stocks Set to Beat Q3 Earnings Estimates on Monday

Axonics (AXNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axonics Modulation Technologies (AXNX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report third quarter 2023 financial results after the close of trading on Monday, October 30. Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following.

Axonics to Report Third Quarter 2023 Financial Results on October 30

Positioned as one of two companies in an underserved healthcare segment with recession-resistant demand for its services and a better product than the legacy monopolist. Strong historical revenue growth while still in the early stages of company maturity and poised to continue to take market share. Demographic tailwinds from an aging population and increased pelvic dysfunction awareness through an aggressive marketing campaign.

Axonics: Growing Duopolist With Superior Product And No Debt

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the following investor conferences in September: Event: Wells Fargo Healthcare Conference Date: Friday, September 8 Presentation time: 10:15 a.m. Eastern Time Event: Morgan Stanley Healthcare Conference Date: Monday, September 11 Presentation time: 10:00 a.m. Eas.

Axonics to Participate in September Investor Conferences

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Dan L. Dearen, president and chief financial officer, is retiring from the company. Kari Keese, vice president of finance and accounting, will succeed Mr. Dearen on Monday, October 2. “On behalf of the Axonics team and the board of directors, I want to thank Dan, my co-fou.

News for Axonics ModulationTechnologies Inc Stock (AXNX)